Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† by Fey, M. F. & Buske, C.
Acute myeloblastic leukaemias in adult patients: ESMO
Clinical Practice Guidelines for diagnosis, treatment
and follow-up†
M. F. Fey1 & C. Buske2, on behalf of the ESMO Guidelines Working Group*
1Department of Medical Oncology, Inselspital and University of Bern, Bern, Switzerland; 2Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research,
University Hospital Ulm, Ulm, Germany
These Clinical Practice Guidelines are endorsed by the Japanese Society of Medical Oncology (JSMO)
incidence and epidemiology
The yearly incidence of acute myeloblastic leukaemia (AML) in
European adults is ﬁve to eight cases per 100 000 individuals
with a steep increase in the population aged over 70 years where
the incidence reaches 15–25/100 000 per annum. The yearly
mortality ﬁgure in AML is four to six cases per 100 000.
diagnosis and pathology/molecular
biology
The diagnosis of AML requires the examination of peripheral
blood and bone marrow specimens. The work-up of these
specimens should include morphology, cytochemistry,
immunophenotyping, cytogenetics and molecular genetics
[chieﬂy polymerase chain reaction (PCR) and ﬂuorescence
in situ hybridisation (FISH) techniques]. See Table 1.
Whilst historically sorted by the largely descriptive French-
American-British (FAB) criteria [1], AML are now classiﬁed
according to the World Health Organisation (WHO)
classiﬁcation from 2001, revised in 2008 [2–4]. The WHO
classiﬁcation incorporates, in addition to morphological criteria,
cytogenetic data, molecular genetics, immunophenotype data
and clinical information into a diagnostic algorithm to delineate
clinically signiﬁcant disease entities. In the WHO classiﬁcation
the term ‘myeloid’ includes all cells belonging to the
granulocytic, monocyte/macrophage, erythroid, megakaryocytic
and mast cell lineage. The percentage of blast cells in the bone
marrow is a practical tool for categorising myeloid neoplasms
into AML or myelodysplastic syndromes (MDS), respectively,
where myeloid neoplasms with more than 20% blasts in the
peripheral blood or bone marrow are considered AML, either de
novo, or having evolved from a pre-existing MDS. Blasts are
deﬁned using the criteria recently proposed by the International
Working Group on Morphology of MDS.
risk assessment and prognostic factors
Patient age, initial leukocyte counts and co-morbidity are
important risk factors. AML having evolved from previously
documented MDS generally have an adverse prognosis.
Molecular and genetic risk stratiﬁcation are the key principles to
guide the therapy of AML, and prognosis is chieﬂy governed by
AML subtypes or entities deﬁned through their karyotype or
speciﬁc molecular features [I, A] [5–11].
karyotype/cytogenetics
The most favourable types of AML are acute promyelocytic
leukaemia (APL) with the chromosomal translocation t(15;17)
(q22;q12), and AML with the t(8;21)(q22;q22), inv(16)
(p13.1q22) or t(16;16)(p13.1;q22) (mostly myelomonocytic
leukaemia with preponderance of eosinophil granulocytes in the
bone marrow), termed core binding factor acute myeloblastic
leukaemia (CBF-AML). Patients with normal karyotype AML
are in an intermediate risk group, and AML with complex
karyotype abnormalities and/or chromosomal monosomies fare
poorly [I, A]. See Table 2.
molecular genetics
Good-risk translocations in AML deﬁned above are all
amenable to detection with molecular techniques (PCR or
FISH) which may be faster than classical cytogenetics, and are
therefore recommended. In cytogenetically normal AML,
somatic mutations of the genes FLT3 (a receptor tyrosine
kinase), NPM1 (nucleophosmin) or CEBPα (a transcription
factor) have been identiﬁed as important prognostic factors.
NPM1 and bi-allelic CEBPαmutations are favourable when
present as single molecular aberrations. FLT3 alterations present
as a single molecular abnormality or with a high allelic ration
predict for a high (and early) relapse rate [10–13]. Patients with
abnormalities of the chromosomal region 11q23 representing
the mixed lineage leukaemia (MLL) gene fare poorly [I, A]. The
list of genes with diagnostic and prognostic value will certainly
increase, for example to include gene mutations in the isocitrate
dehydrogenase (IDH) genes or in the tet oncogene family
member 2 (TET2) genes; in addition, the genes for DNA
(cytosine-5)-methyltransferase 3 α (DNMT3A), Runt-related
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transcription factor 1 (RUNX1) and additional sex combs-like
1 (ASXL1) may be listed. However, these ‘newer’markers do not
have an established use in routine practice at present. Gene
expression proﬁles assessed by microarray technology have been
reported to split AML into deﬁned sub-/categories, but these
techniques are not yet ready for widespread routine use. The
same applies to the techniques of next-generation sequencing of
AML cases.
co-morbidity and other host factors
Patients aged ≥60–65 years are more susceptible to treatment
complications (particularly severe infections) than younger
patients, which contributes to higher risk of an unfavourable
outcome. Pre-existing medical conditions such as diabetes,
coronary heart disease, or chronic pulmonary obstructive
disease must also be recognised as contributing to poor risk. It is
recommended to assess cardiac risk factors at diagnosis, in
addition to clinical examination and cardiac echocardiography.
At diagnosis, patients should be investigated for the presence
of active infection, particularly those planned for intensive
treatment. Careful clinical and haematological assessment is
required to identify such patients where the start of
chemotherapy could or should be delayed, until active infection
has been treated. In addition to clinical examination, additional
techniques recommended are computed tomography (CT)
scans of the chest and the abdomen, and radiological imaging of
teeth and jaws to identify infectious foci such as dental root
granulomas and caries. In addition to haematological and
chemistry laboratory tests, a coagulation status must be obtained
to detect leukaemia-related coagulopathy, particularly in APL;
such tests must be carried out before the insertion of central
intravenous lines.
other pre-treatment investigations
Patients potentially suitable for allogeneic stem cell
transplantation (alloSCT) should be human leukocyte antigen
(HLA) typed at diagnosis, as should their available ﬁrst- and
second-degree family members. In high-risk disease
(e.g. poor-risk karyotype), early matched unrelated donor
(MUD) allogeneic transplantation must be considered, and
therefore, a donor search should be carried out as early as
possible [I, A].
treatment
Whenever possible, AML treatment should be offered in clinical
trials, and given only in experienced centres offering an
adequate multidisciplinary infrastructure as well as a suitably
high case load [14, 15]. Treatment should be planned with
curative intent whenever possible. Intensive chemotherapy of
AML is divided into an induction phase, consolidation and
(rarely) maintenance. Potential candidates for alloSCT
(scheduled for the consolidation phase) must be identiﬁed early
at diagnosis or during induction chemotherapy [I, A].
Treatment of APL differs in several important aspects from
therapy of all other AML types and is, therefore, discussed in a
separate section.
intensive treatment of non-APL AML
All patients undergoing intensive chemotherapy need a central
intravenous line inserted, if necessary, under platelet
transfusion. Induction chemotherapy should only be started
(if possible) when all material needed for diagnostic testing has
been satisfactorily sampled. Patients with excessive
leukocytosis at presentation and with clinical signs of
leukostasis may require emergency leukapheresis coordinated
with the start of chemotherapy. These patients are at particular
risk of a tumour lysis syndrome under induction
chemotherapy and need appropriate monitoring. In these cases
a single injection of rasburicase may be considered to prevent
hyperuricaemia and hence renal failure, but data are
insufﬁcient to support a ﬁrm recommendation in this respect.
In most patients with AML, the start of treatment can safely be
postponed for several days until all diagnostic material has
been collected and the results of analyses such as molecular
typing are available.
Induction chemotherapy should include an anthracycline and
cytarabine with the particularly well-known and time-honoured
‘3 + 7’ regimen [I, A]. Data on dose escalation of daunorubicin
to improve AML outcome look promising, but longer follow-up
is required to support a ﬁrm recommendation [II, C].
Haematopoietic growth factors are an optional adjunct to
intensive induction chemotherapy; however, evidence on their
role in reducing the incidence and/or the severity of infectious
complications during bone marrow aplasia, and evidence on
their putative beneﬁt conferred through priming of leukaemic
cells to increase sensitivity to cytostatic agents, is not convincing
[II, C] [13, 15–20].
Consolidation therapy in AML is warranted once patients
have reached clinical and haematological remission [I, A]. There
is no consensus on a single ‘best’ post-remission treatment
Table 1. Diagnostic work-up in AML
• Bone marrow aspirate and biopsy as well as peripheral blood ﬁlms
• Immunophenotyping of peripheral blood and bone marrow aspirates
• Cytogenetics and molecular genetics (PCR and FISH techniques)
• Routine chemistry including liver and kidney parameters
• Coagulation proﬁle
• Blood group and HLA typing of patient and family members
• Radiology to include dental survey as well as CT scan of chest and
abdomen (or chest X-ray and abdominal ultrasound)
• Sperm preservation in men (according to patient preference)
• Serum pregnancy test in female patients
Table 2. AML risk factors
Favourable APL with t(15;17)
CBF-AML with t(8;21) or inv 16
Biallelic CEBPαmutation with normal cytogenetics
Normal karyotype with NPMmutation and no FLT3 ITD
Intermediate AML with normal cytogenetics and no adverse molecular
features
FLT3 ITD with normal karyotype
Adverse Complex karyotype abnormalities (>3)
Monosomal karyotype
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schedule. In good-risk AML patients in ﬁrst remission, who
have a relapse risk of 35% or less, alloSCT is not justiﬁed
because its toxic effect and/or its risk of transplantation-related
mortality exceed the beneﬁt. Also, these patients may receive
salvage therapy including alloSCT in second remission. Good-
risk AML patients (including NPM-mutated AML with absence
of internal tandem duplications of FLT3 (FLT3-ITD), CBF
AML, and bi-allelic mutant CEBPα AML) as well as patients
who are unsuitable for alloSCT for other reasons should receive
at least one cycle of intensive consolidation chemotherapy
preferably incorporating intermediate or high-dose cytarabine
[I, A]. Patients with AML in intermediate- and poor-risk
groups with an HLA-identical sibling may be candidates for
alloSCT, provided their age and performance status allow for
such treatment [21–32]. Newer data suggest that alloSCT may
no longer be mandatory in intermediate risk patients, but
these data need to be conﬁrmed [III, C] [15]. Patients in these
risk groups without a family donor may qualify for alloSCT
with an HLA-matched unrelated donor identiﬁed through an
international donor registry. In fact, peripheral stem cells
harvested from unrelated HLA-matched donors have become
the most frequently used source of stem cells. If a killer-
immunoglobulin-like receptor (KIR) mismatch is present,
haploidentical transplants may be considered. Conditioning
regimens for alloSCT with dose-reduced chemotherapy
intensity (RIC) may be used for patients in the upper age
range (particularly those >50 years of age), but there is some
evidence that RIC may also be used in adults at a younger age
[II, B]. Infectious disease complications contracted during
induction should be under suitable control before an alloSCT
is enacted. The role of high-dose chemotherapy with
autologous stem cell re-transfusion in AML is still
controversial. Recent data suggest that it may be a good option
(and thus an alternative to alloSCT) in patients in an
intermediate risk group [19]. Whilst it may prolong time to
relapse or remission duration, its potential to prolong overall
survival is uncertain [I, C] [23, 25–27].
non-intensive treatment of AML
Patients with signiﬁcant co-morbidity and the elderly are often
not eligible for intensive treatment. They should receive best
supportive care (BSC) or palliative systemic treatment, which
may incorporate either low-dose cytarabine or a demethylating
agent such as decitabine or azacytidine [II, B]. Excessive
leukocytosis due to spilling of malignant blasts into the
periphery may be reduced with cytoreductive agents such as
hydroxyurea or low-dose cytarabine, which, however, also lower
normal blood cell counts such as red cells, neutrophils or
platelets. Treatment of infections due to neutropenia and
transfusions to cover anaemia or thrombocytopenia are
important additional measures. Erythropoietin is of
questionable value in patients with anaemia due to extensive
inﬁltration of the marrow with leukaemia. In severely
neutropenic patients haematopoietic growth factors may be
tried when neutropenic fever or infections are a problem;
however, there is no evidence to support their continuous use
[II, D] [13, 17, 23, 32–35].
therapy of refractory or relapsed AML
Resistance to therapy (refractory or relapsed AML) is the major
cause of treatment failure, rather than mortality due to
infections and other treatment-related complications. Patients
failing to respond to one or two cycles of induction treatment
are considered refractory and are at very high risk of ultimate
treatment failure. Carefully selected patients with an HLA-
matched donor may be offered alloSCT, albeit with limited
chances of success and at the cost of considerable morbidity
from this procedure [II, B]. For patients unsuited to this
approach, BSC or palliative systemic treatment is often a
reasonable option with, at least, limited toxic effect. The
prognosis of such patients is often dismal regardless of
treatment attempts.
Patients presenting with relapse after a ﬁrst remission may be
offered intensive re-induction, for which chances of success are
better after longer duration of ﬁrst remission. Patients in second
or subsequent remission may still qualify for alloSCT with a
family or unrelated HLA-matched donor, or with cord blood-
derived stem cells.
treatment of APL
Suspicion of or established diagnosis of APL must trigger a
distinctive therapy programme [36–39]. If in doubt and/or if
APL is a diagnostic possibility at presentation, oral all-trans
retinoic acid (ATRA) should immediately be started, and only
discontinued when APL has been speciﬁcally excluded in the
diagnostic work-up of newly diagnosed AML [I, A]. Risk
assessment of APL is chieﬂy based on white blood cell (WBC)
count at presentation, where patients with a WBC count
>10 000/mm3 fare worse. APL induction chemotherapy consists
of ATRA as a differentiating agent and an anthracycline given
simultaneously, but the role of cytarabine in the treatment of
APL is controversial. The use of arsenic trioxide (ATO) in ﬁrst-
line APL therapy is promising, but long-term results are not yet
available. However, the results of ATRA-ATO therapy without
chemotherapy look promising, particularly in good risk APL [II,
C] [40]. The need for daily i.v. application of ATO over a
prolonged period of time, electrolyte as well as cardiac problems
(including potentially fatal torsade-de-pointe ventricular
arrhythmias) and case reports on secondary cancers after ATO
must all be considered. If the results of ASO-ATRA induction
(without chemotherapy) hold true over time, this regime might
well become a new future standard, at least in low- to
intermediate-risk APL [II, C] [40]. Primary resistance of APL is
virtually unheard of and must infer a revision of the initial
diagnosis. APL patients must be followed very closely for the
development of leukaemia-associated coagulopathy and
haemorrhage at presentation and/or under induction. Their
platelet counts should be kept at a minimum of 30–50 G/l.
Fibrinogen should be kept in the normal range (100–150 mg/dl)
throughout induction, whenever possible until signs of
coagulopathy subside. The use of heparin is controversial and is
not recommended as a routine procedure.
The optimal strategy of consolidation in APL is less clear, but
there is consensus on giving two to three anthracycline-
containing chemotherapy cycles [II, B]. A high proportion of
patients reach molecular remission after this treatment series,
clinical practice guidelines Annals of Oncology
vi | Fey and Buske Volume 24 | Supplement 6 | October 2013
where the t(15;17) is no longer PCR-detectable. The small
fraction of patients with persistent molecular disease (i.e. with
the molecular equivalent of the t(15;17) still detectable with
sensitive quantitative PCR assays) may need maintenance
therapy including non-marrow ablative long-term
chemotherapy and ATRA. There is no role for alloSCT in
patients with APL in ﬁrst remission.
In relapsed APL, ATO can induce remissions, even in patients
having turned refractory to ATRA [II, B]. It should be given
until remission is documented. Patients at particularly high risk
for later additional APL relapses may be candidates for alloSCT
or for high-dose chemotherapy consolidation with re-
transfusion of autologous stem cells.
personalised medicine
The impact of molecular AML typing has been demonstrated
extensively for diagnostic purposes (to deﬁne AML entities or
subtypes) and for AML risk assessment (see above section) [5,
6, 9, 12, 13]. However, AML molecular genotyping still has
relatively little practical use in predicting speciﬁc drug
treatment. APL is the only type of AML for which a targeted
agent (ATRA) has become mandatory in routine practice [I, A].
For all other AML entities, targeted agents are either not
available, e.g. for core-binding factor leukaemias, or are still
experimental, e.g. the treatment of FLT-3-positive AML with
the tyrosine kinase inhibitors sorafenib or midostaurin [41]. A
monoclonal antibody targeting the CD33 antigen often present
on AML blasts has shown discordant results in clinical trials;
hence, no ﬁrm recommendation for its routine application can
be given [II, D] [42].
response evaluation and follow-up
Response of AML to treatment is monitored clinically, with
serial peripheral blood counts and repeat bone marrow
examinations. During intensive chemotherapy, bone marrow
should be examined in the aplastic phase to monitor blast
clearance, persistence or early relapse. The usually accepted
criteria of response in AML are blast clearance in the bone
marrow to <5% of all nucleated cells, morphologically normal
haematopoiesis and return of peripheral blood cell counts to
normal levels. Clearance of infections contracted during
therapy-induced aplasia should also be documented.
Patients having concluded treatment should be followed
clinically and with repeated haematological examinations. Serial
bone marrow examinations of patients in remission are of
uncertain value, and cannot therefore be generally
recommended. Although sensitive PCR methods as well as
immunophenotyping are available, permitting molecular
follow-up and detection of minimal residual disease in patients
with suitable markers (mostly speciﬁc chromosomal
translocations, or typical antigen expression proﬁles,
respectively), the early detection of molecular relapse in the
absence of morphological evidence for recurrent AML is of
uncertain therapeutic consequence. Speciﬁcally, evidence that
early re-induction treatment of such patients still in
haematological remission would be of any beneﬁt is lacking.
note
A summary of recommendations is provided in Table 3. Levels
of evidence and grades of recommendation have been applied
using the system shown in Table 4. Statements without grading
were considered justiﬁed standard clinical practice by the
experts and the ESMO faculty.
Table 3. Summary of recommendations
• Diagnostic work-up of AML must in include morphology of peripheral
blood and bone marrow, cytogenetics and molecular genetics assessed
before start of therapy
• HLA-typing of patient and family members to plan for allogeneic stem
cell transplantation where indicated
• AML should only be treated in specialised and experienced centres
offering a multidisciplinary approach, and the possibility of clinical trials
• AML therapy with curative intent includes induction chemotherapy
(incorporating an anthracycline and cytarabine), consolidation which in
intermediate to high-risk patients may incorporate allogeneic stem cell
transplantation
• APL needs a speciﬁc therapy approach. ATRA must be started whenever
in a case of leukaemia the differential diagnosis of APL is considered, and
combined with anthracycline-based chemotherapy once the diagnosis of
APL is conﬁrmed
Table 4. Levels of evidence and grades of recommendation (adapted from
the Infectious Diseases Society of America-United States Public Health
Service Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial of good
methodological quality (low potential for bias) or meta-analyses
of well-conducted randomised trials without heterogeneity
II Small randomised trials or large randomised trials with a suspicion
of bias (lower methodological quality) or meta-analyses of such
trials or of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efﬁcacy with a substantial clinical beneﬁt,
strongly recommended
B Strong or moderate evidence for efﬁcacy but with a limited clinical
beneﬁt, generally recommended
C Insufﬁcient evidence for efﬁcacy or beneﬁt does not outweigh the
risk or the disadvantages (adverse events, costs,…), optional
D Moderate evidence against efﬁcacy or for adverse outcome, generally
not recommended
E Strong evidence against efﬁcacy or for adverse outcome, never
recommended
aDykewicz CA. Summary of the guidelines for preventing opportunistic
infections among hematopoietic stem cell transplant recipients. Clin Infect
Dis 2001; 33: 139–144. By permission of the Infectious Diseases Society of
America.
Annals of Oncology clinical practice guidelines
Volume 24 | Supplement 6 | October 2013 doi:10.1093/annonc/mdt320 | vi
acknowledgements
We are indebted to Alan K. Burnett for helpful critical
comments on the text.
conﬂict of interest
Prof. Buske has reported consultancy/honoraria from Celgene,
Pﬁzer and Roche. Prof. Fey has reported no potential conﬂicts of
interest.
references
1. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classiﬁcation of the
acute leukaemias: French-American-British Cooperative Group. Br J Haematol
1976; 33: 451–458.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. (eds): World Health Organisation (WHO)
Classiﬁcation of Tumours: Pathology and Genetics of Haematopoietic and
Lymphatic Tissues, 3rd edition. Lyon, France: IARC Press, 2001.
3. Vardiman J, Harris NL, Brunning RD. The World Health Organisation (WHO)
classiﬁcation of the myeloid neoplasms. Blood 2002; 100: 2292–2302.
4. Swerdlow SH, Campo E, Harris NL et al. (eds): World Health Organisation (WHO)
classiﬁcation of tumours: pathology and genetics of haematopoietic and lymphatic
tissues, 4th edition. Lyon, France: IARC Press 2008.
5. Schlenk RF, Döhner H, Krauter J et al. Mutations and treatment outcome in
cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:
1909–1918.
6. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA et al. Double CEBPA
mutations, but not single CEBPA mutations, deﬁne a subgroup of acute myeloid
leukaemia with a distinctive gene expression proﬁle that is uniquely associated
with a favorable outcome. Blood 2009; 113: 3088–3091.
7. Falini B, Meducci C, Tiacci E et al. Cytoplasmic nucleophosmin in acute
myelogneous leukaemia with a normal karyotype. N Engl J Med 2005; 352:
254–266.
8. Green CL, Koo KK, Hills RK et al. Prognostic signiﬁcance of CEBPA mutations
in a large cohort of younger adult patients with acute myeloid leukemia: impact of
double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
J Clin Oncol 2010; 28: 2739–2747.
9. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid
leukemia: prognostic and therapeutic implications. J Clin Oncol 2011; 29:
475–486.
10. Kühnl A, Grimwade D. Molecular markers in acute myeloid leukaemia. Int J
Hematol 2012; 96: 153–163.
11. Mrozek K, Marcucci G, Paschka P et al. Clinical relevance of mutations and gene-
expression changes in adult acute myeloid leukemia with normal cytogenetics: are
we ready for a prognostically prioritized molecular classiﬁcation? Blood 2007; 109:
431–448.
12. Pulsoni A, Iacobelli S, Bernardi M et al. M4 acute myeloid leukemia: the role of
eosinophilia and cytogenetics in treatment response and survival. The GIMEMA
experience. Haematologica 2008; 93: 1025–1032.
13. Estey EH. Acute myeloid leukaemia: 2013 update on risk-stratiﬁcation and
management. Am J Hematol 2013; 88: 318–327.
14. Mengis C, Aebi S, Tobler A et al. Assessment of differences in patient populations
selected for or excluded from participation in clinical phase III acute myelogenous
leukemia trials. J Clin Oncol 2003; 21: 3933–3939.
15. Burnett AK, Goldstone A, Hills RK et al. Curability of patients with acute myeloid
leukaemia who did not undergo transplantation in ﬁrst remission. J Clin Oncol
2013; 31: 1293–1301.
16. Roboz GJ. Current treatment of acute myeloid leukemia. Curr Opin Oncol 2012;
24: 711–719.
17. Döhner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid
leukemia in adults: recommendations from an international expert panel, on behalf
of the European LeukemiaNet. Blood 2010; 115: 453–474.
18. Löwenberg B, van Putten W, Theobald M et al. Effect of priming with granulocyte
colony-stimulating factor on the outcome of chemotherapy for acute myeloid
leukemia. N Engl J Med 2003; 349: 743–752.
19. Pﬁrrmann M, Ehninger G, Thiede C et al. Prediction of post-remission survival in
acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol
2012; 13: 207–214.
20. Pabst T, Vellenga E, van Putten W et al. Favorable effect of priming with granulocyte
colony-stimulating factor in remission induction of acute myeloid leukemia restricted
to dose escalation of cytarabine. Blood 2012; 119: 5367–5373.
21. Burnett AK, Hills RK, Milligan DW et al. Attempts to optimise induction and
consolidation treatment in acute myeloid leukaemia: results of the MRC AML 12
trial. J Clin Oncol 2010; 28: 586–595.
22. Koreth J, Schlenk R, Kopecky KJ et al. Allogeneic stem cell transplantation for
acute myeloid leukaemia in ﬁrst complete remission: systematic review, and meta-
analysis of prospective clinical trials. JAMA 2009; 301: 2349–2361.
23. Stone RM. Acute myeloid leukaemia in ﬁrst remission: to choose transplantation or
not? J Clin Oncol 2013; 31: 1262–1266.
24. Cornelissen JJ, van Putten WL, Verdonck LF et al. Results of a HOVON/SAKK
donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell
transplantation in ﬁrst remission acute myeloid leukemia in young and middle aged
adults: beneﬁts for whom? Blood 2007; 109: 3658–3666.
25. Burnett AK, Goldstone AH, Stevens RM et al. Randomised comparison of addition
of autologous bone-marrow transplantation to intensive chemotherapy for acute
myeloid leukaemia in ﬁrst remission: results of MRC AML 10 trial. Lancet 1998;
351: 700–708.
26. Cassileth PA, Harrington DP, Appelbaum FR et al. Chemotherapy compared with
autologous or allogeneic bone marrow transplantation in the management of acute
myeloid leukemia in ﬁrst remission. N Engl J Med 1998; 339: 1649–1656.
27. Zittoun R, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow
transplantation compared with intensive chemotherapy in acute myelogenous
leukaemia. N Engl J Med 1995; 332: 217–223.
28. Mayer RJ, Davis RB, Schiffer CA et al. Intensive post-remission chemotherapy in
adults with acute myeloid leukaemia. N Engl J Med 1994; 331: 896–903.
29. Basara N, Schulze A, Wedding U et al. Early related or unrelated haematopoietic
cell transplantation results in higher overall survival and leukaemia-free survival
compared with conventional chemotherapy in high-risk acute myeloid leukaemia
patients in ﬁrst complete remission. Leukemia 2009; 23: 635–640.
30. Bradstock KF, Matthews JP, Lowenthal RM et al. A randomized trial of high-versus
conventional-dose cytarabine in consolidation chemotherapy for adult de novo
acute myeloid leukemia in ﬁrst remission after induction therapy containing high-
dose cytarabine. Blood 2005; 105: 481–488.
31. Breems DA, Löwenberg B. Acute myeloid leukemia and the position of autologous
stem cell transplantation. Semin Hematol 2007; 44: 259–266.
32. Thomas X, Suciu S, Rio B et al. Autologous stem cell transplantation after
complete remission and ﬁrst consolidation in acute myeloid leukemia patients aged
61–70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Haematologica 2007; 92: 389–396.
33. Kantarjian HM, Thomas XG, Dmoszynska A et al. Multicenter randomized open-label
phase III trial of decitabine versus patient choice, with physician advice, of either
supportive care or low-dose cytarabine for the treatment of older patients with newly
diagnosed acute myeloid leukaemia. J Clin Oncol 2012; 30: 2670–2677.
34. Wheatley K, Goldstone AH, Littlewood T et al. Randomised placebo-controlled trial
of granulocyte colony stimulating factor (G-CSF) as supportive care after induction
chemotherapy in adult patients with acute myeloid leukaemia: a study of the
United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J
Haematol 2009; 146: 54–63.
35. Amadori S, Suciu S, Jehn U et al. Use of glycosylated recombinant human G-CSF
(lenograstim) during and/or after induction chemotherapy in patients 61 years of
age and older with acute myeloid leukemia: ﬁnal results of AML-13, a randomized
phase-3 study. Blood 2005; 106: 27–34.
36. Sanz MA, Grimwade D, Tallman MS et al. Management of acute promyelocytic
leukemia: recommendations from an expert panel on behalf of the European
LeukemiaNet. Blood 2009; 113: 1875–1891.
37. Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all
transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy,
clinical practice guidelines Annals of Oncology
vi | Fey and Buske Volume 24 | Supplement 6 | October 2013
and the role of maintenance therapy in newly diagnosed acute promyelocytic
leukemia. Blood 1999; 94: 1192–1200.
38. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic
leukemia. J Clin Oncol 2011; 29: 495–503.
39. de Botton S, Fawaz A, Chevret S et al. Autologous and allogeneic stem-cell
transplantation as salvage treatment of acute promyelocytic leukaemia initially
treated with all-trans-retinoic acid: a retrospective analysis of the European Acute
Promyelocytic Leukaemia Groups. J Clin Oncol 2005; 23: 120–126.
40. Lo-Coco F, Avvisati G, Vignetti M et al. Retinoic acid and arsenic trioxide for acute
promyelocytic leukemia. N Engl J Med 2013; 369: 111–121.
41. Ravandi F, Alattar ML, Grunwald MR et al. Phase II study of azacytidine plus
sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem
duplication mutation. Blood 2013; 121: 4655–4662.
42. Burnett AK, Hills RK, Milligan D et al. Identiﬁcation of patients with acute
myeloblastic leukaemia who beneﬁt from the addition of gemtuzumab ozogamicin:
results of the MRC AML 15 trial. J Clin Oncol 2011; 29: 369–377.
Annals of Oncology clinical practice guidelines
Volume 24 | Supplement 6 | October 2013 doi:10.1093/annonc/mdt320 | vi
